Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study of AB122-Based Treatments in Advanced Solid Tumors
jRCT2011210020Phase 1Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of zimberelimab in Nonhematologic neoplasms, pancreatic adenocarcinoma (PDAC), colorectal adenocarcinoma and 7 more (15 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities during Cycle 1 (Phase 1a, all cohorts except D-4, D-5, D-9), Adverse events and treatment-related adverse events (Phase 1a, Cohorts D-4, D-5, D-9) and 2 more. Started Sep 2021; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
Nonhematologic neoplasmspancreatic adenocarcinoma (PDAC)colorectal adenocarcinomanon-small cell lung cancer (NSCLC)gastric adenocarcinoma
Beyond the preview
Go deeper on jRCT2011210020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210020.